Hypothesis and TheoryPublished 7 July 2026Δ 9 -tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesisWojciech ŁukowskiFrontiers in Natural Productsdoi 10.3389/fntpr.2026.1812441
ReviewPublished 28 May 2026Structural insights into cannabinoid receptors CB1 and CB2: determinants of ligand selectivityAnn Varghese · Jie Liu · Wenjing Guo · Tucker A. Patterson · Huixiao HongFrontiers in Chemical Biologydoi 10.3389/fchbi.2026.1830007
Original ResearchPublished 15 May 2026Virtual screening and molecular dynamics simulations of cannabinoid receptor 2 agonists as drug candidates for osteoarthritis therapyFernanda F. De Souza · Juliana F. Vilachã · Heberth De Paula · Kathia Maria HonorioFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1809420
ReviewPublished 15 April 2026Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipelineGili Amid-Toby · Omar Alani · Christopher G. BunickFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1766021
Original ResearchPublished 7 January 2026Anti-HER2-targeted therapies: effects on human in vitro blood-brain barrier modelsCarolin J. Curtaz · Rebecca Gebert · Achim Wöckel · Patrick Meybohm · Malgorzata BurekFrontiers in Drug Deliverydoi 10.3389/fddev.2025.1700455
